SOURCE: HCi Viocare

HCi Viocare

March 08, 2016 08:31 ET

HCi Viocare Announces Commencement of Financing Discussions

GLASGOW, SCOTLAND--(Marketwired - Mar 8, 2016) -  HCi Viocare (OTCQB: VICA) ("HCi Viocare", the "Company") today announced entering into discussions with various agents, private individuals and investment firms to raise additional capital for its 2016 and 2017 operations, as well as the expansion of its proposed chain of independent prosthetics and orthotics (P&O) and diabetic foot clinics.

Sotirios Leontaritis, CEO and President of HCi Viocare, stated: "The Company is in active discussions to raise new capital in order to accelerate the expansion of our prosthetics and orthotics (P&O) and diabetic foot clinics into new markets and for certain technology based project costs in relation to commercialization of various applications of our biomedical technologies in the current fiscal year. Our discussions extend to multiple formats for financing including both equity and debt financing, as well as joint venture discussions with third parties in relation to our branded clinics. We have recently engaged various agents who are actively assisting us in our fund-raising efforts."

The securities referred to herein will not be or have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration, under the Act.

Company website:
Glasgow clinic website:
Twitter: @HCiViocare

Glasgow location:
HCi Viocare, Kintyre House, 209 Govan Road, Glasgow G51 1HJ

Forward Looking Statements

This press release contains forward-looking statements. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as "expects", "intends", "estimates", "projects", "anticipates", "believes", "could", and other similar words. All statements addressing product performance, events, or developments that the Company expects or anticipates will occur in the future are forward-looking statements. Because the statements are forward-looking, they should be evaluated in light of important risk factors and uncertainties, some of which are described in the Company's Quarterly, Annual and Current Reports filed with the United States Securities and Exchange Commission (the "SEC"). Should one or more of these risks or uncertainties materialize, or should any of the Company's underlying assumptions prove correct, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on Company's forward-looking statements. In particular, the Company has only recently acquired its first operational Prosthetics & Orthotics (P&O) clinic and is continuing development efforts for its other biomedical technologies, including a its force sensing technology with several potential applications. There is no assurance that the Company will be successful in its ongoing expansion and development efforts, or that it will find suitable commercialization partners for its technologies. Except as required by law, HCi Viocare disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. No stock exchange, securities commission or other regulatory body has reviewed nor accepts responsibility for the adequacy or accuracy of this release. Investors are advised to carefully review the reports and documents that HCi Viocare files from time to time with the SEC, including its Annual, Quarterly and Current Reports.

Contact Information